Abstract
Human ficolin-2 is an important lectin complement pathway activator that is secreted from liver cells and has been implicated as an anti-infection innate immune molecule. However, the role of ficolin-2 protein and its dynamic changes over the course of and in the prognosis of chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC) remain unclear. In this study, we analyzed ficolin-2 protein expression in a cohort of individuals with CHB infection, HCC and cirrhosis. A sandwich enzyme-linked immunosorbent assay (ELISA) method was used to measure serum ficolin-2 concentrations. Ficolin-2 expression in liver tissues was detected by immunohistochemical staining. Serum ficolin-2 concentrations in CHB patients were significantly higher than in healthy controls and HBV carriers. After 48 weeks of routine amelioration liver function treatment, serum ficolin-2 concentrations decreased and were positively correlated with favorable alanine aminotransferase (ALT), HBV DNA and HBeAg-seroconversion outcomes. Interestingly, we observed much lower expression of serum and intrahepatic ficolin-2 in HCC and cirrhosis compared with healthy controls. Our findings suggest that serum and intrahepatic ficolin-2 levels may be considered one of the indicators for the response of chronic HBV infection, HCC and cirrhosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Brown KS, Keogh MJ, Tagiuri N, Grainge MJ, Presanis JS, Ryder SD, Irving WL, Ball JK, Sim RB, Hickling TP. 2007. Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex. Clin Exp Immunol, 147: 90–98.
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. 1994. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology, 19: 1513–1520.
Dunkelberger JR, Song WC. 2010. Complement and its role in innate and adaptive immune responses. Cell Res, 20: 34–50.
Eisen DP, Minchinton RM. 2003. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis, 37: 1496–1505.
El-Serag HB. 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142: 1264–1273.e1261.
Endo Y, Sato Y, Matsushita M, Fujita T. 1996. Cloning and characterization of the human lectin P35 gene and its related gene. Genomics, 36: 515–521.
Esmat S, Omran D, Sleem GA, Rashed L. 2012. Serum mannan-binding lectin in egyptian patients with chronic hepatitis C: its relation to disease progression and response to treatment. Hepat Mon, 12: 259–264.
European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 57: 167–185.
Hoang TV, Toan NL, Song le H, Ouf EA, Bock CT, Kremsner PG, Kun JF, Velavan TP. 2011. ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients. PLoS One, 6: e28113.
Holmskov U, Thiel S, Jensenius JC. 2003. Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol, 21.
Honore C, Rorvig S, Hummelshoj T, Skjoedt MO, Borregaard N, Garred P. 2010. Tethering of ficolin-1 to cell surfaces through recognition of sialic acid by the fibrinogen-like domain. J Leukoc Biol, 88: 145–158.
Hu YL, Luo FL, Fu JL, Chen TL, Wu SM, Zhou YD, Zhang XL. 2013. Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients. Scand J Immunol, 77: 144–150.
Hummelshoj T, Munthe-Fog L, Madsen HO, Fujita T, Matsushita M, Garred P. 2005. Polymorphisms in the FCN2 gene determine serum variation and function of ficolin-2. Hum Mol Genet, 14: 1651–1658.
Hummelshoj T, Munthe-Fog L, Madsen HO, Garred P. 2008. Functional SNPs in the human ficolin (FCN) genes reveal distinct geographical patterns. Mol Immunol, 45: 2508–2520.
Jeong WI, Gao B. 2008. Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol, 23 Suppl 1: S112–118.
Kilpatrick DC, Delahooke TE, Koch C, Turner ML, Hayes PC. 2003. Mannan-binding lectin and hepatitis C infection. Scand J Gastroenterol, 132: 92–95.
Li J, Wu W, Peng G, Chen F, Bai M, Zheng M, Chen Z. 2010. HBcAg induces interleukin-10 production, inhibiting HBcAg-specific Th17 responses in chronic hepatitis B patients. Immunol Cell Biol, 88: 834–841.
Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, Zhang X. 2009. Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol, 6: 235–244.
Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T. 2005. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol, 3150–3156.
Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Association CM. 2006. Diagnostic and treatment guidelines for liver failure. Zhonghua Gan Zang Bing Za Zhi, 14: 643–646. (In Chinese)
Mannan R, Misra V, Misra SP, Singh PA, Dwivedi M. 2014. A comparative evaluation of scoring systems for assessing necro-inflammatory activity and fibrosis in liver biopsies of patients with chronic viral hepatitis. J Clin Diagn Res, 8: FC08–12.
Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, Mizuochi T. 1996. A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J Biol Chem, 271: 2448–2454.
Pan Q, Chen H, Wang F, Jeza VT, Hou W, Zhao Y, Xiang T, Zhu Y, Endo Y, Fujita T. 2012. L-Ficolin Binds to the Glycoproteins Hemagglutinin and Neuraminidase and Inhibits Influenza A Virus Infection Both in vitro and in vivo. J Innate Immun, 4: 312–324.
Poynard T, Yuen MF, Ratziu V, Lai CL. 2003. Viral hepatitis C. Lancet, 362: 2095–2100.
Ren Y, Ding Q, Zhang X. 2014. Ficolins and infectious diseases. Virol Sin, 29: 25–32.
Song WC, Sarrias MR, Lambris JD. 2000. Complement and innate immunity. Immunopharmacology, 49: 187–198.
Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, Hamasaki N. 1998. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem, 273: 20721–20727.
Walport MJ. 2001. Complement. First of two parts. N Engl J Med, 344: 1058–1066.
Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Hai-Jun H. 2013. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS One, 8: e80585.
Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL. 2014. ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape. J Immunol, 193: 783–796.
Author information
Authors and Affiliations
Corresponding authors
Additional information
ORCID: 0000-0003-0826-7327
ORCID: 0000-0002-8283-9381
Rights and permissions
About this article
Cite this article
Chen, T., Hu, Y., Ding, Q. et al. Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases. Virol. Sin. 30, 249–260 (2015). https://doi.org/10.1007/s12250-015-3605-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-015-3605-4